PelvEx 4: Advanced Pelvic Malignancy and the Role of the Multi-disciplinary Team Meeting
1 other identifier
observational
12
1 country
1
Brief Summary
The treatment of locally advanced and recurrent rectal cancers is highly individualized to each patient and their pattern of disease, and this decision is often made at the Multidisciplinary Team (MDT) meeting . The PelvEx collaborative was designed with the intent to provide greater international consensus on appropriate treatment decisions for this cohort. However, we propose that international variation exists in how certain patients will be evaluated, assessed and ultimately treated despite having the same disease. We plan to measure this variation in order to provide a greater understanding of the differences that exist.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Oct 2021
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 19, 2021
CompletedFirst Posted
Study publicly available on registry
October 13, 2021
CompletedStudy Start
First participant enrolled
October 15, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
February 1, 2022
CompletedOctober 13, 2021
October 1, 2021
2 months
April 19, 2021
October 12, 2021
Conditions
Outcome Measures
Primary Outcomes (2)
Regional/geographic variation in MDT treatment allocations
Treatment consensus reached for each individual case
Through study completion, an average of three months
Assessment of resectability
Was the malignancy felt to be resectable by MDT consensus at that institution
Through study completion, an average of three months
Secondary Outcomes (1)
Assessment of staging
Through study completion, an average of three months
Interventions
To assess the geographic variation that exists in the management of locally advanced and recurrent rectal cancers.
Eligibility Criteria
Patients with locally advanced or recurrent pelvic maligancy who have been treated at a participating PelvEx centre.
You may qualify if:
- Complex case from participating PelvEx centre
- Complete clinical information available to allow for informed MDT assessment
- DICOM files for sharing of imaging related to treatment decisions
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- St Vincent's University Hospital, Irelandlead
- PelvEx collaborativecollaborator
Study Sites (1)
St. Vincent's Hospital
Dublin, D4, Ireland
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Consultant Gastrointestinal Surgeon
Study Record Dates
First Submitted
April 19, 2021
First Posted
October 13, 2021
Study Start
October 15, 2021
Primary Completion
December 1, 2021
Study Completion
February 1, 2022
Last Updated
October 13, 2021
Record last verified: 2021-10